The prime time for management of hepatocellular carcinoma in Hong Kong

Chan, Landon L.; Chan, Stephen L.

doi:10.3350/cmh.2023.0094

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are also multiple ongoing trials with lenvatinib in the neoadjuvant and adjuvant settings currently, which should answer all these questions. 33…”

Section: Other First-line Treatmentmentioning

confidence: 99%

Hepatocellular Carcinoma: Advances in Systemic Therapy

Selene,

Ozen,

Patel

2024

Semin intervent Radiol

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a prevalent primary liver cancer, representing over 90% of cases globally and ranking as the third leading cause of cancer-related death. This article reviews the evolving landscape of systemic therapies for advanced HCC, emphasizing recent advancements and their impact on patient outcomes. The advent of molecular targeted therapies has transformed HCC management, with sorafenib being the first FDA-approved molecular targeted therapy, setting a standard for a decade. However, recent breakthroughs involve the combination of atezolizumab and bevacizumab, demonstrating superior outcomes over sorafenib, leading to FDA approval in 2020. Another notable combination is tremelimumab and durvalumab, showing efficacy in a multinational phase III trial. Beyond these combinations, this article explores the role of other first-line treatments and subsequent therapies after progression. The evolving landscape of systemic therapies for HCC reflects a paradigm shift, with immunotherapy combinations emerging as key players alongside targeted therapies. This article highlights the complexity of treatment decisions, considering individual patient characteristics and disease etiology, and underscores the ongoing quest to optimize both systemic and local–regional therapies for improved long-term outcomes in HCC patients.

show abstract

“…There are also multiple ongoing trials with lenvatinib in the neoadjuvant and adjuvant settings currently, which should answer all these questions. 33…”

Section: Other First-line Treatmentmentioning

confidence: 99%

Hepatocellular Carcinoma: Advances in Systemic Therapy

Selene,

Ozen,

Patel

2024

Semin intervent Radiol

View full text Add to dashboard Cite

show abstract

“…Considering the current landscape of immune-checkpoint inhibitors for advanced-stage HCC, it is imperative to reassess the position of multikinase inhibitors like sorafenib or lenvatinib. 8 Firstly, Yoo et al 9 conducted a multinational, multicenter retrospective cohort study to examine the clinical outcomes of multikinase inhibitors as a second-line regimen following progression on Ate/Bev regimen. Among 49 patients in the study, 59.2% utilized sorafenib, 38.8% used lenvatinib, and 1% used cabozantinib as subsequent therapy.…”

mentioning

confidence: 99%

The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma

Kim

2024

Gut and Liver

View full text Add to dashboard Cite

The prime time for management of hepatocellular carcinoma in Hong Kong

Cited by 2 publications

References 26 publications

Hepatocellular Carcinoma: Advances in Systemic Therapy

Hepatocellular Carcinoma: Advances in Systemic Therapy

The Position of Multikinase Inhibitors in the Era of Immune-Checkpoint Inhibitors for Hepatocellular Carcinoma

Contact Info

Product

Resources

About